Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

Abstract Background Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FG...

Full description

Bibliographic Details
Main Authors: Eudocia Q. Lee, Alona Muzikansky, Dan G. Duda, Sarah Gaffey, Jorg Dietrich, Lakshmi Nayak, Ugonma N. Chukwueke, Rameen Beroukhim, Lisa Doherty, Caroline Kane Laub, Debra LaFrankie, Brittney Fontana, Jennifer Stefanik, Sandra Ruland, Victoria Caruso, Jennifer Bruno, Keith Ligon, David A. Reardon, Patrick Y. Wen
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Medicine
Subjects:
angiogenesis
bevacizumab‐refractory
FGFR
glioblastoma
VEGFR
Online Access:https://doi.org/10.1002/cam4.2505

Internet

https://doi.org/10.1002/cam4.2505

Similar Items